Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: According to July PR Patents came out stronger

Carlsbad, CA and Cupertino, CA - July 27, 2010 - Patriot Scientific Corporation (OTC Bulletin Board: PTSC News), The TPL Group and Alliacense today announced their latest success in overcoming attempts to challenge the validity of the MMP Portfolio(TM). The United States Patent and Trademark Office (USPTO) has issued a Notice of Intent to Issue Reexamination Certificate for the US '336 patent indicating that all claims will be allowed with no amendments to the claim language. The US '336 patent, along with the entire MMP Portfolio(TM), enables technology that is essential for virtually all microprocessor-based products used today............................

We have eagerly awaited the completion of the US '336 reexamination process," stated Carlton Johnson, chairman of the executive committee of Patriot's Board of Directors. "Not only have the majority of original claims in this patent survived, but it has been further strengthened by the addition of new claims. This represents an important victory for the MMP Portfolio."

"This victory coupled with other reexam successes significantly strengthens the MMP Portfolio and magnifies the risk for those companies without a license to the technology," said Dan Leckrone, Chairman of The TPL Group, adding "an enormous amount of credit is due to the Alliacense team whose research, analysis, and strategy continues to be instrumental to our success."

More than 75 global, market-leading companies from the US, Europe, Japan, Korea, Taiwan and China have licensed the MMP Portfolio(TM) technologies, resulting in over $300 million in licensing revenue. The MMP Portfolio has also been successful in litigation, with eight litigants purchasing licenses

Share
New Message
Please login to post a reply